(NASDAQ: EVAX) Evaxion A's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.
Evaxion A's earnings in 2026 is -$7,707,000.On average, 6 Wall Street analysts forecast EVAX's earnings for 2026 to be -$357,294,816, with the lowest EVAX earnings forecast at -$670,219,687, and the highest EVAX earnings forecast at -$17,514,452. On average, 6 Wall Street analysts forecast EVAX's earnings for 2027 to be -$476,393,088, with the lowest EVAX earnings forecast at -$780,560,733, and the highest EVAX earnings forecast at -$13,135,839.
In 2028, EVAX is forecast to generate -$257,337,338 in earnings, with the lowest earnings forecast at -$482,231,238 and the highest earnings forecast at -$13,135,839.